- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, MEDI5083 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Combination therapy, Metastases: MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. (clinicaltrials.gov) - Jul 27, 2020
P1, N=39, Completed,
Active, not recruiting --> Completed
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, MEDI5083 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. (clinicaltrials.gov) - Feb 17, 2020
P1, N=38, Active, not recruiting,
In vivo, this translates to enhanced control of both poorly- and well-infiltrated syngeneic tumors and generation of durable memory in mice with complete tumor regression. Trial completion date: Jan 2020 --> May 2020 | Trial primary completion date: Jan 2020 --> May 2020
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, MEDI5083 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. (clinicaltrials.gov) - Aug 8, 2019
P1, N=38, Active, not recruiting,
The toxicity profile does not support further development of the subcutaneous formulation of this drug. N=495 --> 38 | Trial completion date: Aug 2022 --> Dec 2019 | Trial primary completion date: Aug 2022 --> Dec 2019
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, MEDI5083 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Enrollment change, Combination therapy, Metastases: MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. (clinicaltrials.gov) - May 13, 2019
P1, N=495, Active, not recruiting,
N=495 --> 38 | Trial completion date: Aug 2022 --> Dec 2019 | Trial primary completion date: Aug 2022 --> Dec 2019 Recruiting --> Active, not recruiting | N=204 --> 495
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, MEDI5083 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Combination therapy, Metastases: MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. (clinicaltrials.gov) - Apr 22, 2017
P1, N=204, Recruiting,
Recruiting --> Active, not recruiting | N=204 --> 495 Not yet recruiting --> Recruiting
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, MEDI5083 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P1 trial, Combination therapy, Metastases: MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. (clinicaltrials.gov) - Mar 24, 2017
P1, N=204, Not yet recruiting,
|
